ArticlePain research & management2026
Purine Metabolism-Related Pathogenic Genes in Trigeminal Neuralgia: A Multiomics Mendelian Randomization Study.
Article in Pain research & management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Purine Metabolism-Related Pathogenic Genes in Trigeminal Neuralgia: A Multiomics Mendelian Randomization Study.Pain research & management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeTo investigate the association between purine metabolism-related genes and trigeminal neuralgia (TN) using multiomics approaches.
methodsA multiomics summary-data-based Mendelian randomization (SMR) approach was applied to investigate associations between purine metabolism-related genes and TN. Genome-wide association study (GWAS) data from FinnGen R10 were integrated with blood-derived DNA methylation quantitative trait loci (mQTL), expression quantitative trait loci (eQTL), and protein quantitative trait loci (pQTL) datasets. Associations were evaluated by colocalization and replication in UKBB (G6_TRINEU) and FinnGen R12. Drug-target MR analysis used blood eQTL variants as proxies for gene expression. GEO transcriptomic and single-cell RNA sequencing (scRNA-seq) datasets and GTEx brain tissue eQTL data provided expression and tissue-level validation. Functional enrichment, protein-protein interaction network, and druggability analyses were performed.
resultsSMR analysis identified 238 mQTLs (127 genes), 30 eQTLs, and 3 pQTLs associated with TN. Colocalization supported 96 mQTLs (23 genes), 18 eQTLs, and 3 pQTLs, with 42 mQTLs and the CNOT7 eQTL validated in UKBB. POMGNT2 showed genetically predicted associations with TN at both gene and protein levels. Integrative analysis highlighted ATP6V0E2, PLAT, and VKORC1 with evidence of epigenetic regulation. Drug-target MR provided supportive evidence that genetically proxied expression of CNOT7 and PLAT may be associated with lower TN risk. Transcriptomic validation showed downregulation of ATP6V0E2, PLAT, and CNOT7 after trigeminal nerve injury. Brain eQTL analysis supported the association of CNOT7 with TN across multiple brain regions. scRNA-seq revealed cell-type-specific expression patterns of prioritized genes in trigeminal ganglion tissues. Functional enrichment indicated involvement in stress response, metabolism, and genome maintenance pathways. PPI analysis identified six hub genes: ABCB1, COMT, GFM1, MDH2, NRAS, and TXN. Druggability analysis showed that ATP6V0E2, PLAT, and VKORC1 are targetable by existing drugs.
conclusionThis study prioritizes purine metabolism-linked genes showing genetically supported associations with TN and highlights potential biological pathways and therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.